烟酸缓释剂（ER）/辛伐他汀（Simcor®）：在血脂调节中的应用指南。
Niacin extended release (ER)/simvastatin (Simcor®): a guide to its use in lipid regulation.
机构信息
Adis, a Wolters Kluwer Business, Auckland, New Zealand.
出版信息
Drugs R D. 2010;10(4):253-60. doi: 10.2165/11202560-000000000-00000.
Abstract
Oral fixed-dose niacin extended release/simvastatin is associated with clinically relevant improvements in plasma lipid profiles, including lowering of non-high-density lipoprotein cholesterol levels, relative to simvastatin monotherapy in patients with mixed dyslipidemias who had not responded fully to simvastatin monotherapy, and is generally well tolerated.
摘要
口服固定剂量烟酸缓释/辛伐他汀与辛伐他汀单药治疗相比，可使混合性血脂异常患者的血脂谱得到临床相关改善，包括降低非高密度脂蛋白胆固醇水平，这些患者对辛伐他汀单药治疗反应不完全，且通常具有良好的耐受性。
相似文献
1
Niacin extended release (ER)/simvastatin (Simcor®): a guide to its use in lipid regulation.
Drugs R D. 2010;10(4):253-60. doi: 10.2165/11202560-000000000-00000.
2
Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
Am J Cardiovasc Drugs. 2008;8(2):69-81. doi: 10.2165/00129784-200808020-00001.
3
Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin.
Vasc Health Risk Manag. 2009;5(1):31-43. doi: 10.2147/vhrm.s3190. Epub 2009 Apr 8.
4
Targeting multiple dyslipidemias with fixed combinations--focus on extended release niacin and simvastatin.
Vasc Health Risk Manag. 2008;4(5):1001-9. doi: 10.2147/vhrm.s3460.
5
Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
Am J Cardiol. 2003 Mar 15;91(6):667-72. doi: 10.1016/s0002-9149(03)00007-9.
6
Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy.
Vasc Health Risk Manag. 2012;8:39-44. doi: 10.2147/VHRM.S22601. Epub 2012 Jan 25.
7
Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany.
Eur J Health Econ. 2012 Jun;13(3):365-74. doi: 10.1007/s10198-011-0309-z. Epub 2011 Apr 5.
8
Effects of low-dose of niacin associated to simvastatin in the treatment of mixed dyslipidemia Salgad.
Minerva Cardioangiol. 2010 Oct;58(5):531-42.
9
Niacin extended-release therapy in phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis.
Am J Cardiovasc Drugs. 2011 Jun 1;11(3):179-87. doi: 10.2165/11592560-000000000-00000.
10
Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders.
Expert Rev Cardiovasc Ther. 2008 Nov;6(10):1303-10. doi: 10.1586/14779072.6.10.1303.
引用本文的文献
1
Quantification of Niacin and Its Metabolite Nicotinuric Acid in Human Plasma by LC-MS/MS: Application to a Clinical Trial of a Fixed Dose Combination Tablet of Niacin Extended-Release/Simvastatin (500 mg/10 mg) in Healthy Chinese Volunteers.
Int J Anal Chem. 2015;2015:212437. doi: 10.1155/2015/212437. Epub 2015 Aug 5.
本文引用的文献
1
Efficacy and safety of combination therapy with niacin extended-release and simvastatin versus atorvastatin in patients with dyslipidemia: The SUPREME Study.
J Clin Lipidol. 2009 Apr;3(2):109-18. doi: 10.1016/j.jacl.2009.02.009. Epub 2009 Feb 11.
2
Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study.
J Clin Lipidol. 2008 Apr;2(2):79-90. doi: 10.1016/j.jacl.2008.02.004. Epub 2008 Feb 15.
3
The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration.
J Am Coll Cardiol. 2010 Jun 15;55(24):2721-6. doi: 10.1016/j.jacc.2010.03.017.
4
Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study.
J Am Coll Cardiol. 2009 Nov 3;54(19):1787-94. doi: 10.1016/j.jacc.2009.06.036.
5
Combined use of extended-release niacin and atorvastatin: safety and effects on lipid modification.
Chin Med J (Engl). 2009 Jul 20;122(14):1615-20.
6
The mechanism and mitigation of niacin-induced flushing.
Int J Clin Pract. 2009 Sep;63(9):1369-77. doi: 10.1111/j.1742-1241.2009.02099.x.
7
Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia.
Am J Cardiovasc Drugs. 2009;9(2):69-79. doi: 10.1007/BF03256578.
8
Flushing ASsessment Tool (FAST): psychometric properties of a new measure assessing flushing symptoms and clinical impact of niacin therapy.
Clin Drug Investig. 2009;29(4):215-29. doi: 10.2165/00044011-200929040-00001.
9
Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study).
Am J Cardiol. 2008 May 15;101(10):1428-36. doi: 10.1016/j.amjcard.2008.02.092.
10
Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
Am J Cardiovasc Drugs. 2008;8(2):69-81. doi: 10.2165/00129784-200808020-00001.
Zotero 插件